Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 431 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... July 7, 2021 如果您剛確診為肺癌患者，請來看看專家的回答 April 22, 2021 FDA Proposes Rule Prohibiting Menthol Cigarettes June 27, 2022 Working Mom with Stage II Breast Cancer Receives Custom Wig Made... July 30, 2020 Load more HOT NEWS Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... Finding Hope in the New Year During COVID-19 and Cancer EMA Recommends Granting a Marketing Authorisation for Capmatinib NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia
